Figure 10.

Significant reduction of human PCC primary culture viability (n = 6) by clinically relevant doses of BYL719, everolimus, and the combination of BYL719 plus everolimus at 72 h of treatment, showing a synergistic effect (@) of 5 µM BYL719 plus 10 nM everolimus. A significant reduction of human PCC primary culture viability (n = 6) by sunitinib and the combination of sunitinib plus everolimus is seen at 72 h. Sunitinib and everolimus did not act synergistically. The arithmetic means and all single values of six human PCC cultures from six different patients are shown. *Statistically significant different results in comparison with the DMSO control (P < 0.05).